Investigating immune cells in acute graft-versus-host disease
A Prospective Study on the Correlation Between Tissue-resident Immune Cell Subsets and Graft-versus-host Disease Following Hematopoietic Stem Cell Transplantation.
This study is looking at how certain immune cells affect the development and progression of acute graft-versus-host disease in people who have had a stem cell transplant.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Nanfang Hospital, Southern Medical University Academic / other |
| Locations | 1 site (Guangzhou, Other (Non U.s.)) |
| Trial ID | NCT06708507 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the role of tissue-resident immune cell subsets in the development and progression of acute graft-versus-host disease (aGVHD) following hematopoietic stem cell transplantation. It will enroll 40 participants, divided into two groups based on the severity of their aGVHD, and will follow them for three months to evaluate their condition and overall survival. The study does not involve any randomization or treatment protocols, allowing physicians to make treatment decisions based on clinical judgment. Participants will be monitored monthly for aGVHD evaluation and other relevant outcomes.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 16-65 who are experiencing their first episode of clinically diagnosed aGVHD.
Not a fit: Patients with a history of other tumors, uncontrolled infections, or other autoimmune diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of aGVHD and lead to improved management strategies for patients undergoing stem cell transplantation.
How similar studies have performed: While similar studies have explored immune responses in aGVHD, this specific focus on tissue-resident immune cell subsets is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Voluntarily sign the informed consent form; 2. Age 16-65 years old 3. Clinically diagnosed with GVHD for the first time/receiving GVHD treatment. Exclusion Criteria: 1. Have a history of other tumors 2. With poor compliance or mental disorders 3. Infected with HIV and HCV 4. With uncontrolled HBV infection 5. With other autoimmune diseases 6. Those who are judged by the researcher to be unsuitable to participate in this study
Where this trial is running
Guangzhou, Other (Non U.s.)
- Nanfang Hospital, Southern Medical University — Guangzhou, Other (Non U.s.), China (Recruiting)
Study contacts
- Principal investigator: Hua Jin — Nanfang Hospital, Southern Medical University
- Study coordinator: Yiming Sun
- Email: 1224940802@qq.com
- Phone: +86 13917802810
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.